Cargando…
Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in france, germany and belgium – a retrospective database study
INTRODUCTION: Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. OBJECTIVES: To assess risk factors of treatment discontinuation in patients on paliperidone p...
Autores principales: | Cai, R., Decuypere, F., Chevalier, P., Wimmer, A., Guillon, P., Pype, S., Godet, A., Timtschenko, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471791/ http://dx.doi.org/10.1192/j.eurpsy.2021.437 |
Ejemplares similares
-
Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium
por: Cai, Rui, et al.
Publicado: (2022) -
Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France
por: Limosin, Frédéric, et al.
Publicado: (2018) -
S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020) -
Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018) -
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)